VPVilja Pietiäinen

Vilja Pietiäinen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vilja Pietiäinen has a total of 259 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neuroblastoma immune microenvironment is characterized by limited T cell infiltration and abundant macrophages expressing targetable receptors

    by Ruth Nousiainen, Minttu Polso, Lassi Paavolainen, Aino Mutka, Veikka Valtanen, Satu Långström, Minna Koskenvuo, Virve Pentikäinen, Marjut Pihlajoki, Katja Eloranta, et al.

    Background & Aim: Neuroblastoma (NBL) is a heterogenous pediatric malignancy ranging from low-risk infant tumors to high-mortality stage IV disease. We aimed to characterize the composition and spatial organization of the tumor immune microenvironment (TIME) across different tumor stages and assess the prevalence of immunotherapeutic targets, particularly focusing on macrophage-directed therapies. Methods: Multiplexed immunofluorescence staining was performed on 185 retrospective formalin-fixed paraffin-embedded tissue cores from 39 NBL patients. Four antibody panels targeting a total of 32 proteins were used. Immune and stromal cell phenotypes and their spatial location were identified by single-cell image analysis and correlated with clinical features such as stage, MYCN status, prior treatment, and survival. Results: Immune infiltration varied among samples and patients. CD45 + leukocytes comprised a median of 1.8% of all cells (range 0.2-51.0%, IQR 0.8-6.5%), dominated by tumor-associated macrophages (TAMs; 31.7% of CD45 + cells), and NK cells (15.6%). Stage IV tumors contained fewer lymphocytes. Chemotherapy shifted the TIME toward a macrophage-dominated, lymphocyte-depleted profile. Rather than segregating into M1- and M2-like subsets, TAMs co-expressed pro- and anti-inflammatory markers: CD40, CSF1R, and CD163 were broadly expressed, Clever-1 was detected on 41% of macrophages, and CD200R was virtually absent. CD47 + CD45 − cells were enriched in stage IV tumors. In univariate Cox analysis, higher fractions of total CD45 + , NK, NKT-like, B, and cytotoxic T cells were associated with improved overall survival. Higher proportion of CD47 + CD45 - cells predicted worse survival. Blood leukocyte counts did not correlate with intratumoral immune infiltration. Conclusions: The NBL TIME was heterogenous. High-risk tumors shared a lymphocyte-depleted, myeloid-skewed phenotype, whereas higher overall immune content predicted better survival. Macrophages were present in all tumors and expressed targetable receptors (CD40, CSF1R, CD163, Clever-1). CD47, enriched in high-risk disease, could also be a candidate macrophage-directed target.

  • Open Access

    Novel therapeutic strategies for ccRCC through integration of systemic drug combinations and oncolytic adenovirus immunotherapy

    by Michaela Feodoroff, Isabel Mogollon, Firas Hamdan, Tamara J. Luck, Romika Kumari, Paolo Bottega, Janita Sandberg, Erika Romppanen, Lassi Paavolainen, Minna Malmstedt, et al.

    Introduction: Clear cell renal cell carcinoma (ccRCC) remains a significant therapeutic challenge due to its biological heterogeneity, variable clinical behavior, and limited efficacy of single-agent systemic therapies. Combination strategies targeting multiple tumor-promoting pathways may improve therapeutic outcomes. Methods: We evaluated combination treatment strategies integrating targeted systemic drugs with oncolytic adenovirus therapy using representative patient-derived cancer cell (PDC) models. Anti-tumor efficacy and immune-mediated cytotoxicity were assessed to investigate treatment responses across different patient-derived models. Results: Combination treatment enhanced anti-tumor activity compared with either monotherapy alone and promoted immune-mediated cytotoxicity involving CD8+ T cells and natural killer (NK) cells. Treatment responses varied across the three PDC models, reflecting interpatient heterogeneity and suggesting potential value for biomarker-guided patient stratification. Discussion: These findings demonstrate the potential of combining targeted therapy with oncolytic virotherapy to overcome current therapeutic limitations in ccRCC. Moreover, the use of advanced three-dimensional human-relevant PDC models provides a scalable platform for evaluating combination therapies, supporting personalized treatment strategies, and facilitating the development of therapeutic approaches applicable to ccRCC and other cancer types.


  • Open Access

    Pathway-centric multi-omics and functional precision medicine reveal shared drug vulnerabilities in heterogeneous adult Wilms tumor

    by Minttu Polso, Romika Kumari, Tamara Luck, Piia Mikkonen, Katja Välimäki, Ruusu-Maaria Merivirta, Minna Malmstedt, Johanna Lehtonen, Erika Romppanen, Sara Kuusela, et al.

    Wilms tumor, i.e., nephroblastoma, is rare in adults and lacks standardized treatment, complicating clinical decision-making. Within the functional precision medicine study (DEDUCER), we profiled two spatially distinct tumor regions (T1 and T2) of an adult Wilms tumor patient using integrated histopathology, whole-exome sequencing, FFPE transcriptomics, and ex vivo drug screening of short-term cultured patient-derived cancer cells (PDCs) with 528 compounds. Genomic profiling revealed a truncal ASXL1 frameshift and shared F7, UBA1, COL21A1, and ATM variants alongside region-specific alterations: a TP53 mutation and broad copy-number (CN) gains in T1, versus ARID1A and KMT2D stop-gains in copy-neutral T2. Transcriptomics of tumor areas identified convergent activation of the G2/M checkpoint, E2F targets, and mitotic spindle programs across regions, consistent with high proliferation and partially comparable biomarker signatures to those observed in an open-source pediatric Wilms tumor dataset (n = 130). Functional assays uncovered distinct and shared drug vulnerabilities: although ATM alterations were present in both tumors, T1 PDCs showed selective sensitivity to topoisomerase I and BCL-2 inhibition in the context of an additional T1-specific TP53 alteration, while broader single-agent sensitivity and stronger drug synergies were observed in T2. Pathway-centric data integration indicated that differential gene expression and copy-number gains, rather than single mutations alone, better predicted ex vivo drug responses, revealing actionable shared dependencies despite pronounced spatial heterogeneity and establishing a translational framework for individualized management in this rare disease.

  • Open Access

    Site-Dependent Decoupling of Drug-Biomarker Associations in Clear Cell Renal Cell Carcinoma Revealed by Functional Profiling of Patient-Derived Cell Models

    by Michaela Feodoroff, Tamara J. Luck, Romika Kumari, Minttu Polso, Patrick Penttilä, Minna Malmstedt, Piia Mikkonen, Lauren J. Gerber, Ruusu Merivirta, Mariliina Arjama, et al.

    Clear cell renal cell carcinoma (ccRCC) frequently exhibits primary and acquired resistance to standard-of-care therapies, underscoring the need for improved strategies to predict therapeutic response and prioritize patient-specific treatments. Although recent multi-omic and single-cell studies have provided insight into the molecular landscape of ccRCC, molecular alterations alone incompletely predict drug sensitivity. We prospectively profiled tumors from 28 patients with localized and metastatic ccRCC by integrating molecular characterization, functional drug sensitivity and resistance testing in patient-derived cell models, and longitudinal clinical data. Although genomic biomarkers suggested potentially actionable therapies in 27/28 patients, functional testing revealed discordance between genomic actionability and ex vivo drug sensitivity, whereas linear mixed-effects modelling uncovered 16 novel copy-number-based features associated with sensitivity to 11 drugs. Genotype-drug response associations were largely preserved between primary tumors and vena cava thrombi but frequently disrupted in distant metastases. Integrating functional drug testing with multi-omic profiling reveals vulnerabilities not apparent from genomic data alone, refines therapeutic actionability, captures interpatient and intersite heterogeneity in ccRCC, and provides a scalable framework for individualized treatment prioritization.


  • Image-based profiling of healthy donor immune cells with Blood Cell Painting

    by Lassi Paavolainen, Caroline Högel-Starck, Veera A. Timonen, Gantugs Atarsaikhan, Isabel Mogollon, Minttu Polso, Antti Hassinen, Vilja Pietiäinen, Esa Pitkänen

    BioStudies – one package for all the data supporting a study

  • Open Access

    Functional screening identifies kinesin spindle protein inhibitor filanesib as a potential treatment option for hepatoblastoma

    by Ruth Nousiainen, Katja Eloranta, Jani Saarela, Antti Hassinen, Tamara J. Luck, Stefano Cairo, Emilie Indersie, Swapnil Potdar, Michaela J. Feodoroff, Jouko Lohi, et al.

    Hepatoblastoma is a rare pediatric liver malignancy usually treated with surgery and chemotherapy. To explore new treatment options for hepatoblastoma, drug screening was performed using six cell models established from aggressive hepatoblastoma tumors and healthy pediatric primary hepatocytes. Of the 527 screened compounds, 98 demonstrated cancer-selective activity in at least one hepatoblastoma model. The kinesin spindle protein (KSP) inhibitor filanesib was effective in all models and was further evaluated. Filanesib induced G2/M arrest and apoptosis in hepatoblastoma cells at concentrations tolerable to primary hepatocytes. Prominent nuclear fragmentation was observed in filanesib-treated hepatoblastoma cells. Genes participating in cell cycle regulation were noted to be differentially expressed after filanesib treatment. Filanesib reduced the rate of tumor growth in 4/5 hepatoblastoma mice models. One of these models showed complete growth arrest. Our results suggest that filanesib is a potential candidate for hepatoblastoma treatment and should be investigated in future clinical trials.


  • Open Access

    Distinct molecular profiles and shared drug vulnerabilities in pancreatic metastases of renal cell carcinoma

    by Matilda Roos-Mattila, Pauliina Kallio, Tamara J. Luck, Minttu Polso, Romika Kumari, Piia Mikkonen, Katja Välimäki, Minna Malmstedt, Pekka Ellonen, Teijo Pellinen, et al.

    Clear-cell renal cell carcinoma (ccRCC) is the most common origin of pancreatic metastases (PM). Distinct genomic aberrations, favorable prognosis, and clinical observations on high angiogenesis, and succeeding tyrosine kinase inhibitor (TKI) sensitivity have been reported in PM-ccRCC. However, no functional or single-cell studies have been conducted thus far. We recruited five PM-ccRCC patients and investigated the genomic, single-cell transcriptomic, and drug sensitivity profiles of their patient-derived cells (PDCs). The PM depicted both expected and novel genomic alterations. Further, the transcriptomics differed from both primary and metastatic ccRCC, with upregulations of the PI3K/mTOR and – supporting the clinical observations – angiogenesis pathways. Data integration at pathway level showed that transcriptomics explained drug sensitivities the best. Accordingly, PM-ccRCC PDCs shared sensitivity to many PI3K/mTOR inhibitors. Altogether, we show distinct genomic and transcriptomic signatures in PM-ccRCC, highlight the superiority of transcriptomics in interpreting drug sensitivities, and encourage the use of TKIs and PI3K/mTOR inhibitors in PM-ccRCC.


  • Open Access

    Achieving high-resolution single-cell segmentation in convoluted cancer spheroids via Bayesian optimization and deep-learning

    by Isabel Mogollon, Michaela Feodoroff, Anna Nylund, Alba Montedeoca, Gantugs Atarsaikhan, Pedro Neto, Peter Horvath, Antti Rannikko, Vincenzo Cerullo, Vilja Pietiäinen, et al.

    Understanding cellular function within 3D multicellular spheroids is essential for advancing cancer research, particularly in studying cell-stromal interactions as potential targets for novel drug therapies. However, accurate single-cell segmentation in 3D cultures is challenging due to dense cell clustering and the impracticality of manual annotations. We present a high-throughput (HT) 3D single-cell analysis pipeline that combines optimized wet-lab conditions, deep learning (DL)-based segmentation models, and Bayesian optimization to address these challenges. By using live-cell nuclear and cytoplasmic dyes, we achieved clear and uniform staining of cell populations in renal cancer and immune T-cell monocultures and cocultures, improving single-cell detection in spheroids. Our pipeline integrates image preprocessing and DL models based on 3DUnet architecture, enabling robust segmentation of densely packed 3D structures. Bayesian optimization, guided by a custom objective function, was employed to refine segmentation parameters and improve quality based on biologically relevant criteria. The pipeline successfully segments cells under various drug treatments, revealing drug-induced changes not detectable by bulk conventional assays. This approach has potential for application to more complex biological samples, including, organoid co-cultures, diverse drug treatments, and integration with additional immunostaining assays, paving the way for detailed HT analyses of single-cell responses.


  • Open Access

    Image-based profiling of healthy donor immune cells with Blood Cell Painting reveals novel genotype-phenotype associations

    by Caroline Högel-Starck, Veera A. Timonen, Gantugs Atarsaikhan, Isabel Mogollon, Minttu Polso, Antti Hassinen, Jarno Honkanen, Cindy David Sarmento, Jessica Koski, Julius Soini, et al.

    The morphological diversity of blood immune cells of healthy individuals, critical for recognizing disease-related phenotypes, remains largely uncharacterized. To address this gap, we developed Blood Cell Painting (BCP): a high content, high throughput fluorescence imaging assay for peripheral blood mononuclear cells. We generated a BCP Atlas with images of 50 million cells from 390 healthy blood donors, identifying 18 distinct immune cell morphology clusters. A genome-wide association study of BCP-derived imaging-based cellular features revealed 93 significant associations across 30 genetic loci. These loci include genes linked to mast cell function, inflammation, immune signaling, mitochondrial maintenance and circadian immune modulation. We also observed correlations between immune cell morphological features and clinical traits, such as respiratory conditions and healthcare visits related to contraceptive management, potentially reflecting hormonal influences on immune cell phenotypes. As a proof of concept for clinical application, acute myeloid leukemia subtypes were distinguished by BCP. Our study establishes BCP as a versatile method for immune cell profiling to uncover genetic, phenotypic and clinical determinants of immune cell morphology in health and disease.


  • Open Access

    Distinct Molecular Profiles and Drug Vulnerabilities in Pancreatic Metastases of Renal Cell Carcinoma

    by Matilda Juusola, Pauliina Kallio, Tamara Luck, Minttu Polso, Romika Kumari, Piia Mikkonen, Katja Välimäki, Minna Malmstedt, Pekka Ellonen, Teijo Pellinen, et al.

    Pancreatic metastases (PM) of clear cell renal cell carcinoma (ccRCC) are rare, and little is known about them at patient level. The aim of this study was to define the patient-specific characteristics of PM-ccRCC and matching patient-derived cell (PDC) cultures. We describe the genomic and single-cell transcriptomic profiles of five patients with PM-ccRCC as well as the functional drug sensitivities of their PDCs­­. First, the patients’ tumors depicted both common and novel somatic mutations and copy number alterations, which were maintained in their PDCs. Second, we show that PM-ccRCC transcriptomes differ from previously reported signatures for bone metastasis and primary ccRCC. Finally, we find both shared (e.g., PIK3, mTOR inhibitors) and patient-specific (e.g., EGFR, MEK1/2 inhibitors) drug sensitivities. We use integrated multi-omics to illuminate pathway-level deregulations explaining drug sensitivities, and to propose patient-specific druggable pathways. Altogether, our findings suggest enriched molecular profiles in PM-ccRCC and target pathways for PM-ccRCC treatment.